Sartorius Stedim Biotech Stock
Stocks
DIM
FR0013154002
Medical Equipment, Supplies & Distribution
OTC Markets Traded|
Market Closed -
Euronext Paris
19:55:00 10/11/2026 +03
|
After hours 21:57:57 | |||
| 223.40 EUR | -1.24% |
|
221.90 | -0.67% |
| 10-26 | Sartorius Stedim Biotech : Jefferies reiterates its Buy rating | ZD |
| 10-23 | Sartorius Stedim Biotech : JP Morgan maintains a Buy rating | ZD |
| Market Cap | 22.01B 24.54B 20.28B 18.42B 34.86B 2,301B 35.83B 243B 96.76B 1,233B 92.1B 90.15B 3,897B | P/E 2026 * |
57.6x | P/E 2027 * | 44x |
|---|---|---|---|---|---|
| Enterprise Value | 24B 26.77B 22.12B 20.09B 38.02B 2,509B 39.08B 265B 106B 1,344B 100B 98.32B 4,250B | EV / Sales 2026 * |
7.66x | EV / Sales 2027 * | 6.82x |
| Free-Float |
28.47% | Yield 2026 * |
0.37% | Yield 2027 * | 0.44% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| DIM | Real-time | |
CBOE
| DIMp | Real-time | |
|
Börse Stuttgart
| 56S1 | Delayed | |
|
CBOE
| 0NK7 | Real-time | |
|
Tradegate
| 56S1 | Real-time | |
|
Boerse Muenchen
| 56S1 | Real-time | |
|
OTC Markets
| SDMHF | Delayed | |
|
Deutsche Boerse AG
| 56S1 | Delayed | |
|
London S.E.
| 0NK7 | Delayed | |
|
Xetra
| 56S1 | Delayed | |
|
Borsa Italiana
| 4DIM | End-of-day quote | |
|
Wiener Boerse
| DIM | End-of-day quote |
Last Transcript: Sartorius Stedim Biotech
| 1 day | -1.24% | ||
| 1 month | +4.98% | ||
| 3 months | +23.15% | ||
| 6 months | +35.97% | ||
| Current year | +6.38% |
| 1 week | 218 |  | 229.8 |
| 1 month | 208 | | 229.8 |
| Current year | 150 | | 229.8 |
| 1 year | 150 | | 229.8 |
| 3 years | 139.1 | | 281 |
| 5 years | 139.1 | | 544 |
| 10 years | 50.13 | | 551 |
| Manager | Title | Age | Since |
|---|---|---|---|
René Fáber
CEO | Chief Executive Officer | 51 | 28/03/2023 |
| Chief Tech/Sci/R&D Officer | 62 | 08/09/2011 | |
Petra Müller
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 07/04/2015 | |
Susan Dexter
BRD | Director/Board Member | 70 | 07/04/2015 |
Lothar Kappich
BRD | Director/Board Member | 69 | 14/09/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 12/17/25 A | Sell | Company | 750,000 | 0.7706% | ||
| 2/16/24 A | Buy | Chief Executive Officer | 1,716,739 | 1.8624% | ||
| 3/2/22 A | Sell | Company | 200,442 | 0.2174% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.24% | 0.00% | +19.34% | +20.76% | 24.66B | |
| -0.52% | +0.43% | -12.73% | +16.91% | 191B | |
| -1.25% | +2.56% | +9.44% | +43.48% | 126B | |
| -1.47% | +3.38% | -9.57% | +17.33% | 124B | |
| -1.57% | +1.82% | -39.83% | +7.26% | 98.14B | |
| +1.20% | +2.66% | -4.14% | +76.93% | 65.98B | |
| -0.52% | +8.02% | +17.85% | -8.77% | 58.63B | |
| -1.26% | +3.56% | -1.92% | +62.33% | 55.67B | |
| +1.42% | -5.09% | -7.57% | +50.74% | 48.78B | |
| +1.08% | +3.41% | +4.00% | -4.71% | 36.03B | |
| Average | -0.41% | +2.22% | -2.51% | +28.23% | 83B | |
| Weighted average by Cap. | -0.65% | +2.48% | -6.54% | +27.04% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.13B 3.49B 2.89B 2.62B 4.96B 328B 5.1B 34.57B 13.77B 175B 13.11B 12.83B 555B | 3.48B 3.89B 3.21B 2.92B 5.52B 364B 5.67B 38.45B 15.32B 195B 14.58B 14.27B 617B |
| Net income | 384M 428M 354M 321M 608M 40.14B 625M 4.24B 1.69B 21.51B 1.61B 1.57B 67.99B | 489M 546M 451M 410M 775M 51.16B 797M 5.4B 2.15B 27.41B 2.05B 2B 86.65B |
| Net Debt | 1.99B 2.22B 1.84B 1.67B 3.16B 209B 3.25B 22.01B 8.77B 112B 8.35B 8.17B 353B | 1.74B 1.94B 1.61B 1.46B 2.76B 182B 2.84B 19.24B 7.66B 97.65B 7.3B 7.14B 309B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/11/26 | €223.40 | -1.24% | 86,541 |
| 09/11/26 | €226.20 | +0.18% | 76,715 |
| 06/11/26 | €225.80 | +0.71% | 105,334 |
| 05/11/26 | €224.20 | +0.27% | 104,689 |
| 04/11/26 | €223.60 | +0.09% | 100,657 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- DIM Stock
Select your edition
All financial news and data tailored to specific country editions
